TY - JOUR
T1 - Neonatal BCG vaccination and atopic dermatitis before 13 months of age
T2 - A randomized clinical trial
AU - Thøstesen, Lisbeth Marianne
AU - Kjaergaard, Jesper
AU - Pihl, Gitte Thybo
AU - Birk, Nina Marie
AU - Nissen, Thomas Nørrelykke
AU - Aaby, Peter
AU - Jensen, Aksel Karl Georg
AU - Olesen, Annette Wind
AU - Stensballe, Lone Graff
AU - Jeppesen, Dorthe Lisbeth
AU - Benn, Christine Stabell
AU - Kofoed, Poul-Erik
N1 - This article is protected by copyright. All rights reserved.
PY - 2018/2
Y1 - 2018/2
N2 - Background: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis. Methods: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months. Results: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P =.04). Conclusion: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).
AB - Background: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis. Methods: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months. Results: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P =.04). Conclusion: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).
KW - Journal Article
KW - Bacillus Calmette-Guérin
KW - infants
KW - atopic dermatitis
KW - heterologous immunity
KW - randomized controlled trial
KW - Humans
KW - Infant
KW - Male
KW - BCG Vaccine/therapeutic use
KW - Female
KW - Dermatitis, Atopic/epidemiology
KW - Netherlands/epidemiology
KW - Infant, Newborn
U2 - 10.1111/all.13314
DO - 10.1111/all.13314
M3 - Journal article
C2 - 28929567
SN - 0105-4538
VL - 73
SP - 498
EP - 504
JO - Allergy
JF - Allergy
IS - 2
ER -